Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatolimab + Tovolimab + regorafenib + paclitaxel as second-line therapy in advanced gastric or gastroesophageal junction adenocarcinoma after chemo-immunotherapy failure
ChiCTR2500106665Phase 2Not yet recruiting
- Sponsor
- Affiliated Cancer Hospital of Nanjing Medical University
- Start
- Jul 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sintilimab + tovolimab in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by Affiliated Cancer Hospital of Nanjing Medical University. Primary endpoint: Objective response rate. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
sintilimab + tovolimab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2500106665.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500106665.